drugset / Trial / NCT00577993
Fludarabine, Mitoxantrone, and Dexamethasone (FND) Plus Rituximab for Lymphoma Patients
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The goal of this clinical research study is to compare chemotherapy given with rituximab to chemotherapy followed by rituximab. The safety of both treatment schedules will be studied. Laboratory tests of genetic changes in blood and bone marrow before and during the study will also be monitored.
Timeline
- Start
- 1998-03-16
- Primary completion
- 2017-08-24
- Completion
- 2017-08-24
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Bleomycin | Unknown | 5 unknown | Intravenous |
| Comparator | Cisplatin | Other / unclassified | 25 mg/m2 | Intravenous |
| Comparator | Cyclophosphamide | Other / unclassified | 750 mg/m2 | Intravenous |
| Comparator | Cytarabine | Small molecule | 1.5 unknown | Intravenous |
| Comparator | Dexamethasone | Small molecule | 20 mg | Intravenous |
| Comparator | Dexamethasone | Small molecule | 40 mg | Intravenous |
| Comparator | Doxorubicin | Other / unclassified | 25 mg/m2 | Intravenous |
| Comparator | Etoposide | Small molecule | 40 mg/m2 | Intravenous |
| Comparator | Fludarabine | Small molecule | 25 mg/m2 | Intravenous |
| Comparator | Methylprednisolone | Other / unclassified | 500 mg | Intravenous |
| Comparator | Mitoxantrone | Small molecule | 10 mg/m2 | Intravenous |
| Comparator | Prednisone | Other / unclassified | 100 mg | Oral |
| Comparator | Rituximab | Monoclonal antibody | 375 mg/m2 | Intravenous |
| Comparator | Vincristine | Small molecule | 0.7 mg/m2 | Intravenous |
| Comparator | Vincristine | Small molecule | 1.4 mg/m2 | Intravenous |
| Comparator | interferon alfa-2b | Protein / enzyme biologic | 3 unknown | Subcutaneous |
| Comparator | procarbazine | Small molecule | 100 mg/m2 | Oral |